CG Oncology, Inc.

CGON Nasdaq CIK: 0001991792

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
Mailing Address 3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
Phone (949) 409-3700
Fiscal Year End 1231
EIN 371611499

Financial Overview

FY2025

$752.60M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 13, 2026 View on SEC
4 Insider stock transaction report March 6, 2026 View on SEC
10-K Annual financial report February 27, 2026 View on SEC
8-K Current report of material events February 27, 2026 View on SEC
8-K Current report of material events January 13, 2026 View on SEC
4 Insider stock transaction report January 13, 2026 View on SEC
424B5 Prospectus supplement January 13, 2026 View on SEC
8-K Current report of material events January 9, 2026 View on SEC

Annual Reports

10-K February 27, 2026
  • Completed pivotal Phase 3 BOND-003 trial enrollment for cretostimogene in NMIBC, reducing development risk.
  • Maintained a strong cash position of $320.0 million, funding operations into late 2027.
View Analysis

Insider Trading

STRONG SELL 1 insiders 4 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.